TheraRadar
Data updated: May 26, 2026

DOBUTAMINE HYDROCHLORIDE IN DEXTROSE 5% IN PLASTIC CONTAINER (dobutamine hydrochloride)

Cardiovascular Approved 1993-09-27

DOBUTAMINE HYDROCHLORIDE IN DEXTROSE 5% IN PLASTIC CONTAINER is indicated for the treatment of Cardiac Decompensation; Heart Disease; Congestive Heart Failure.

Source: FDA Label • Baxter
1
Indication
--
Phase 3 Trials
32
Years on Market

Details

Status
Prescription
First Approved
1993-09-27
Routes
INJECTION
Dosage Forms
INJECTABLE

Companies

Active Ingredient: DOBUTAMINE HYDROCHLORIDE

DOBUTAMINE HYDROCHLORIDE IN DEXTROSE 5% IN PLASTIC CONTAINER Approval History

1994
1995
1996
1997
1998
1999
2000
2001
2002
2003
2004
2005
2006
2007
2008
2009
2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
2026
Original
New Indication
New Form
Label Update
148 FDA actions from 1993 to 2025
Nov 2025 SUPPL
Mfg · Manufacturing (CMC)
Jun 2024 SUPPL
Label · Labeling
Sep 2023 SUPPL
Label · Labeling

What DOBUTAMINE HYDROCHLORIDE IN DEXTROSE 5% IN PLASTIC CONTAINER Treats

3 indications

DOBUTAMINE HYDROCHLORIDE IN DEXTROSE 5% IN PLASTIC CONTAINER is approved for 3 conditions since its original approval in 1993. These indications span multiple therapeutic areas including oncology, immunology, and more.

  • Cardiac Decompensation
  • Heart Disease
  • Congestive Heart Failure
Source: FDA Label

DOBUTAMINE HYDROCHLORIDE IN DEXTROSE 5% IN PLASTIC CONTAINER Competitive Set

Pro

Three rings of competition based on shared molecular targets and treated indications.

Unlock 8 more competitors across all three rings.
Upgrade to Pro

Filters applied: drops same-active-ingredient (505(b)(2) reformulations), route-mismatch (topical vs systemic), and cross-therapeutic-area matches in same-indication rings.

Drugs Similar to DOBUTAMINE HYDROCHLORIDE IN DEXTROSE 5% IN PLASTIC CONTAINER

3 of 20

FDA-approved drugs for similar conditions. Compare mechanisms and indications to understand treatment alternatives.

DOBUTAMINE HYDROCHLORIDE
DOBUTAMINE HYDROCHLORIDE
3 shared
Pfizer
Shared indications:
Cardiac DecompensationHeart DiseaseCongestive Heart Failure
ACETAZOLAMIDE
ACETAZOLAMIDE
1 shared
Sun Pharma
Shared indications:
AMILORIDE HYDROCHLORIDE
AMILORIDE HYDROCHLORIDE
1 shared
CHARTWELL RX
Shared indications:
📋

Clinical Trial Registry

2 trials
Trial Sponsor ID Phase Status Title
NCT04893655 DOBU whipple BC-08919 Ph 4 completed Effect of Dobutamine on Hepatic Blood Flow During Goal-directed Hemodynamic Therapy
NCT03098680 PRIME PRIME (A094136) Ph 1 terminated A Study of the Pharmacokinetic and Pharmacodynamic Responses in Healthy and Altered Human Cardiovascular Systems
🔬

Active Pipeline

Pro

Ongoing clinical trials by development phase

Loading...

Key Completed Trials

Pro

Completed studies with published results, ranked by significance

Loading...
📊

Trial Timeline

Full development history with FDA approval milestones

|
Loading...
Understanding FDA Approval Types
Count Type What it means
- ORIG Original approval - drug first enters market
- SUPPL - Efficacy New indication (new disease/condition approved)
- SUPPL - Labeling Label text changes (warnings, dosing updates)
- SUPPL - Manufacturing Production changes (new facility)
- SUPPL - Chemistry Formulation changes (new dosage strength)

Green lines in the timeline show ORIG and Efficacy approvals - the clinically meaningful milestones.

DOBUTAMINE HYDROCHLORIDE IN DEXTROSE 5% IN PLASTIC CONTAINER FDA Label Details

Indications & Usage

FDA Label (PDF)

DOBUTAMINE HYDROCHLORIDE IN DEXTROSE 5% IN PLASTIC CONTAINER is indicated for the treatment of Cardiac Decompensation; Heart Disease; Congestive Heart Failure.

Track DOBUTAMINE HYDROCHLORIDE IN DEXTROSE 5% IN PLASTIC CONTAINER with TheraRadar Pro

Watchlist alerts, full database access, CSV exports across 14,000+ drugs.

Upgrade to Pro

Data Sources

Data sourced from official FDA and NIH databases. Click links to verify on original sources.